The Food and Drug Administration (FDA) has approved Weltruza ™ (olanzapine) as the first once-monthly subcutaneous long-acting injectable (LAI) for the treatment of schizophreni ...
Phase 3 ONWARD3 data demonstrate sustained skin clearance, pruritus relief, and quality of life improvements with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results